WO1997021728A1 - PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) - Google Patents

PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) Download PDF

Info

Publication number
WO1997021728A1
WO1997021728A1 PCT/SE1996/001621 SE9601621W WO9721728A1 WO 1997021728 A1 WO1997021728 A1 WO 1997021728A1 SE 9601621 W SE9601621 W SE 9601621W WO 9721728 A1 WO9721728 A1 WO 9721728A1
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
bonded
wherem
peptide
compound
Prior art date
Application number
PCT/SE1996/001621
Other languages
French (fr)
Inventor
Christer Nordstedt
Jan NÄSLUND
Johan Thyberg
Lars O. Tjernberg
Lars Terenius
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9504467A external-priority patent/SE9504467D0/en
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to EP96940740A priority Critical patent/EP0866805A1/en
Priority to AU10728/97A priority patent/AU1072897A/en
Publication of WO1997021728A1 publication Critical patent/WO1997021728A1/en
Priority to US09/095,106 priority patent/US6331440B1/en
Priority to US09/850,061 priority patent/US20020094957A1/en
Priority to US10/721,774 priority patent/US7288523B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the present invention relates to compounds, which are of special interest by their ability to bind to the KLVFF-sequence in the peptide amyloid ⁇ and to inhibit polymerization of the amyloid ⁇ peptide.
  • the compounds according to the invention are e.g. useful as medicaments and as tools for identifi ⁇ cation of substances to be used m the treatment or prevention of amyloidosis.
  • Amyloidosis is a condition which is characterized by the deposition of amyloid in organs or tissues of the human or animal body, either as a primary disease of unknown cause or secondary to chronic disease, such as tuberculosis or osteomyeli- tis.
  • AD Alzheimer's disease
  • the pre-eminent neuropathological feature of Alzheimer's disease (AD) is the deposition of amyloid in the brain parenchyma and cerebrovasculature (D.J. Selkoe, Neuron 6, 487-498 (1991) ; D.J. Selkoe, Annu . Rev. Cel l Biol . 10, 373-403 (1994) ) .
  • amyloid ⁇ The basic component of such amyloid is a peptide termed amyloid ⁇ , or A ⁇ (G.C. Glenner, CW. Wong, Bi ochem . Biophys . Res . Commun . 120, 885-890 (1984) ) . It is a 40 to 42 ammo acids long proteolytic frag ⁇ ment of the Alzheimer amyloid precursor protein (APP) , a protein expressed m most tissues (J. Kang, et al . , Na ture 325, 733-736 (1987)) . Genetic and neuropathological studies provide strong evidence for a central role of A ⁇ in the pathogenesis of AD, but the pathophysiological consequences of the amyloid deposition are still unclear.
  • APP Alzheimer amyloid precursor protein
  • a ⁇ polymers and amyloid are toxic to neurons, either directly or indirectly, and hence cause neurodegeneration (C. Behl, J. B. Davis, R.Lesley, D. Schubert, Cell 77, 817-827 (1994) ; D.T. Loo, et al . , ibid 90, 7951-7955 (1995) ) .
  • amyloid associated with Alzheimer' s disease consists of thin fibrils of polymerized A ⁇ .
  • a rational pharmacological approach for the prevention of amyloidogenesis would therefore be to use drugs that specifically interfere with A ⁇ -A ⁇ interaction and polymerization.
  • Previous studies showed that A ⁇ polymerization m vi vo and m vi tro is a highly specific process, which probably involves an mtei- action between binding sequences in the A ⁇ peptide (J. Naslund, et a l . , Proc . Na tl . Aca d . Sci . USA 91, 8378-8382 (1994) ; J. Naslund, et al . , Biochem . Bio ⁇ phys . Res . Commun . 204, 780-787 (1994) ) .
  • Wood et al (S.J. Wood, R. Wetzel, J.D. Martin, M.R. Hurle, Biochemis try 34, 724-730 (1995) ) suggest that amino acid residues within or close to A ⁇ -16-20 are important for the adoption of the correct ⁇ -pleated sheet structure of A ⁇ and show that ammo acids 17-23 in the amyloid ⁇ peptide (A ⁇ ) are essen- tial for fibril formation and probably make up the ⁇ -sheet core of the fibrils.
  • Wood et al. have investigated the ability of their peptides to form amyloid fibrils in a solution containmg solely the mutated or the wild-type peptide. However, no method or principle which makes it possible to inhibit A ⁇ of wild type from forming amyloid fibrils is devised and no use of the peptides as medicaments is suggested.
  • WO 95/08999 relates to amelioration of amnesia in Alzheimer's disease caused by deposition of amy ⁇ loid ⁇ protein.
  • Three peptides are disclosed, which overcome the amnestic effects of ⁇ -12-28, a peptide homologous to A ⁇ .
  • WO 95/08999 describes the screening of several other peptides, which were neither significantly amnestic nor memory enhancing, of which one is KLVFF, SEQ. NO. 15 of the sequence listing therein.
  • amyloid ⁇ pep- tide (A ⁇ ) nto amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease.
  • a ⁇ molecules interact with a high degree of specificity during polymerization and fibril for- matron. It was assumed that ligands which bind to recognition sequences would be capable of inhibiting A ⁇ polymerization and possibly also dissolve pre ⁇ formed A ⁇ polymers m si tu . The strategy in finding such A ⁇ ligands was to identify critical binding re- gions m A ⁇ and, based on their sequences, develop a compound capable of blocking the A ⁇ -A ⁇ binding.
  • Lys-Leu-Val-Phe-Phe (KLVFF) sequence in A ⁇ is necessary for polymerization to occur.
  • Pep- tides incorporating this sequence bind to A ⁇ and are capable of blocking the fibril formation of A ⁇ -1-40 and are therefore potentially useful as drugs.
  • compounds have been found, which
  • Lys-Leu-Val-Phe- Phe (16-20) motif serves as a structural basis for the development of peptide and non-peptide agents aimed at inhibiting amyloidogenesis m vi vo .
  • the present invention relates to compounds which are able to bind to the Lys-Leu-Val-Phe-Phe-sequence, or KLVTF-sequence, in the peptide amyloid ⁇ . More specifi ⁇ cally, the compounds according to the invention are defined by their formula (I) : Ri - A' - Y' - Leu - X' - Z' - B' - R 2 (I) m which X' means any group or ammo acid imparting to the com ⁇ pound of formula (I) the ability to bind to the KLVFF- sequence m amyloid ⁇ peptide, or two ammo acids impart ⁇ ing the same ability, but with the proviso that one is not proline;
  • Y' means any amino acid
  • Z' means any non-acidic ammo acid
  • A' means a direct bond or an ⁇ -amino ac d bonded at the carboxyl terminal of the ⁇ -carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the ⁇ -carboxy group;
  • B' means a direct bond or an ⁇ -amino acid bonded at the ⁇ -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the ⁇ -nitrogen of the N-termmal ⁇ -amino acid;
  • Ri is H or -CO-Rj bonded at the ⁇ -amino group of A' ;
  • R 2 is H, -ORi or NR 5 R 6 , all bonded to the ⁇ -carboxyl group of the ⁇ -carboxytermmal of B' ;
  • R is a straight or branched carbon chain of 1-4 carbon atoms
  • R 4 is a straight or branched carbon chain of 1-4 carbon atoms
  • R 6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH 2 ) n -, where n is 4-5; Ri and Ri together can form a hydrocarbon ring or heterocyclic ring; and all the ⁇ -ammo acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe.
  • alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
  • cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
  • Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an ammo or a methoxy, ethoxy, propoxy or butoxy group.
  • the compound exhibits an ability to inhibit polymeriza ⁇ tion of amyloid ⁇ peptide.
  • all the ammo acids of the compound are D-isomers.
  • Y' is Lys
  • Z' is Phe, resulting in a compound of the followmg formula: Ri-A' -NH-CHf- (CH ? ) 4 -NH 2 ]-CO-Leu-X' -NH-CH[-CH 2 -Ph]-CO-B' -R 2
  • Ri-A' -NH-CHf- (CH ? ) 4 -NH 2 ]-CO-Leu-X' -NH-CH[-CH 2 -Ph]-CO-B' -R 2 In an alternative embodiment of the invention,
  • Ri is acetyl
  • Ri is H. According to another embodiment, R ? is H. Al ⁇ ternatively, Ri and R? are both H.
  • a second aspect of the present invention is the use of a compound of formula:
  • X' means any group or ammo acid imparting to the com- pound of formula (II) the ability to bind to the KLVFF- sequence in amyloid ⁇ peptide, or two ammo acids impart ⁇ ing the same ability, but with the proviso that one is not proline;
  • Y' means any ammo acid;
  • Z' means any non-acidic amino acid;
  • A' means a direct bond or an ⁇ -ammo acid bonded at the carboxyl terminal of the ⁇ -carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the ⁇ -carboxy group;
  • B' means a direct bond or an ⁇ -ammo acid bonded at the ⁇ -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the ⁇ -nitrogen of the N-termmal ⁇ -amino acid;
  • R x is H or -CO-R 3 bonded at the ⁇ -amino group of A' ;
  • R ? is H, -OR 4 or NR 5 R 6 , all bonded to the ⁇ -carboxylgroup of the ⁇ -carboxytermmal of B' ;
  • R 3 is a straight or branched carbon chain of 1-4 carbon atoms
  • R is a straight or branched carbon chain of 1-4 carbon atoms
  • R 5 and R 6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH 2 ) n - where n is 4-5; Ri and R 2 can together form a hydrocarbon ring or heterocyclic ring; and all the ⁇ -amino acids can be either D- or L-isomers; for inhibition of polymerization of amyloid ⁇ pep ⁇ tide, as a model substance for synthesis of amyloid ⁇ peptide-ligands for inhibition of polymerization of amyloid ⁇ peptide, as a tool for the identification of other organic compounds with similar functional properties or as ligand for detection of amyloid de ⁇ posits using e.g. positron emission tomography (PET) .
  • alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
  • cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
  • Ar yl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.
  • a compound is used, wherein all the amino acids are D-isomers.
  • Y' is Lys.
  • Z' is Phe, resulting in a compound of the followmg formula:
  • a compound is used, wherein Y' is Phe while Z' is any non-acidic ammo acid.
  • a compound is used, wherem X' is Val-Val.
  • Ri is acetyl.
  • Ri and/or R 2 are H.
  • Yet another aspect of the present invention is a compound according to the mvention for use as a medicament .
  • a compound prefera ⁇ bly of the formula (I) or (II), which is able to bind to the KLVFF-sequence in amyloid ⁇ peptide and which has the ability to inhibit polymerization of amyloid ⁇ peptide, for the manufacture of a medicament for the treatment or prevention of amyloidosis, especially in the treatment or prevention of Alz ⁇ heimer s disease associated with amyloidosis, for the treatment or prevention of demens in patients with Down s syndrome, for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) or for the prevention of fibril forma ⁇ tion of human amyloid protem.
  • a last aspect of the present invention is a composition
  • a composition comprising a compound according to formula II and optionally a ligand capable of binding or interacting with the compound according to formula II and a carrier.
  • Said composition can e.g. be adapted for injec ⁇ tion a liquid carrier or for oral administration in a tablet or capsule.
  • Carriers are known for persons skilled in the art .
  • K is lysine (Lys)
  • L is leucine (Leu)
  • V is valine (Val)
  • F is phenylalanine (Phe)
  • A is alanine (Ala)
  • E is glutamic acid (Glu) .
  • any group giving the compound ac- cording to formula (I) the ability to bind to the KLVFF-sequence in the amyloid ⁇ peptide means that this group gives the compound a structure, which can fulfil the requirements given in claim 1.
  • the hydrocarbon ring or heterocyclic ring has preferably 4-6 atoms, preferably C, N and S.
  • Fig. 2A Ten-mers corresponding to consecutive sequences of A ⁇ -1-40. Radioactivity bound to the filter was detected by autoradiography and quantified by densitometry.
  • Fig. 2B EVHHQKLVFF and N and C-terminal trun ⁇ cated fragments were synthesized and analyzed for affinity to 125 I-labelled A ⁇ -1-40.
  • Fig. 2C Each ammo acid residue in KLVFF was systematically replaced with Ala and analyzed for affinity to 125 I-labelled A ⁇ -1-40.
  • Fig 2D ⁇ ensorgram from surface plasmon reso- nance spectroscopy (BIAcore 2000) .
  • Fig. 3 A and B Content of non-aggregated peptide in the supernatants from incubations of wild- type and Ala-substituted A ⁇ -1-28 as analyzed by HPLC.
  • a region located in the central part of A ⁇ displayed prominent binding of radioactive A ⁇ -1-40.
  • Another binding region was the hydrophobic C-termmus of the molecule (D. Burdick, et al , J.
  • the run ⁇ ning buffer consisted of 10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA and 0.05% surfactant P20 as described. [U. Jansson, M. Malmqvist, Adv. Bi osens . 2, 291-336 (1992)]) .
  • the binding was not saturable, indicating that A ⁇ -1-40 bound to immobilized KLVFF could inter ⁇ act with other A ⁇ -1-40 molecules m a polymerization reaction.
  • AA served as linker between the active peptide and the chip (upper trace) and cysteine alone , indi ⁇ cating non-specific binding, (C) as control (lower trace) . Arrows indicate start and stop of injection (Fig. 2D) .
  • Example 2 To investigate if the KLXXF motif was required for A ⁇ polymerization, we synthesized A ⁇ -1-28, a well-studied A ⁇ fragment that readily forms amyloid fibrils (D.A. Kirschner, et a l . , Proc . Na tl . Acad . Sci . USA 84, 6953-6957 (1987); CJ. Barrow, M.G. Zagorski, Science 253, 179-82 (1991); C. Nordstedt, et a l . , J. Biol . Chem . 269, 30773-30776 (1994)) and mutated A ⁇ -1-28 where the KLVFF sequence was substi ⁇ tuted with AAVFA (A ⁇ -1-28 AAVFA ) .
  • AAVFA A ⁇ -1-28 AAVFA
  • FIG. 3 A A ⁇ -1-28 (Fig. 3 A) and A ⁇ -1-28 AAVFA (Fig. 3 B) were incubated at 200 ⁇ M in TBS for 24 h at 37°C in a shaking water bath. After incubation, the tubes were centrifuged at 20,000g for 20 mm and the content of non-aggregated peptide in the supernatants (Fig. 3 A, B) was analyzed using an established C4 RPLC system (12) whereas the aggregated peptides in the pellets were analyzed by electron microscopy after adsorp ⁇ tion to formvar-coated grids and negative staining with 2°o uranyl acetate in water.
  • a ⁇ -1-40 was incubated at 100 ⁇ M m TBS for 48 h at 37 C C in a shaking water bath, either alone or together with 100 ⁇ M AcKLVFFWH2- The polymerized material was ad ⁇ sorbed to formvar-coated grids and negatively stained with 2° uranyl acetate in water.
  • the peptides were synthesized essentially as described by Frank (Frank R, 1992, Tetrahedron 42:9217-9232) . Briefly, a spacer corresponding to 2 molecules of ⁇ -alanme was coupled to cellulose me - branes (Whatman XX) . The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated ammo acids (AMS biotech ⁇ nology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.
  • the KLXXF motif in the A ⁇ molecule is not only critical for polymerization and fibril formation.
  • Durmg non-amyloidogenic processing of APP the mole- cule is cleaved between ammo acid residues Y ⁇ anc ⁇ L 17 (F.S. Esch, et a l . , Science 248, 1122-1124 (1990)), leading to the formation of a fragment of A ⁇ termed p3 and corresponding to A ⁇ -17-40 or A ⁇ -17-42 (C Haass, A.Y. Hung, M.G. Schlossraum, D.B. Teplow, D. J. Selkoe, J. Biol . Chem . 268, 3021-3024 (1993)) .
  • KLVFF binds stereo specifically to the homologous sequence in A ⁇ (i.e. A ⁇ -16-20) .
  • D-pentapeptides that interact with nonrelevant regions in A ⁇ was eliminated.
  • the D-amino acid ligands were found not only to bind to A ⁇ but also to inhibit amyloid fibril formation. Since peptides built up of D-amino acids are resistant to proteolytic degradation, these ligands may be beneficial for inhibition of amyloidogenesis in vivo.
  • KLVFF will be useful in the identi ⁇ fication of small organic molecules (e.g. by screening of substance libraries) with the ability to bind to A ⁇ in this relevant region and inhibit amyloid fibril formation (candidate drugs for the treatment of Alzheimer disease and other related amyloidoses) . Discussion and conclusion
  • Cyclodextrins have primarily been used to increase the solubility of a wide range of lipophilic drugs and it is unlikely that they would display any speci ⁇ ficity for A ⁇ m vi vo .
  • Congo red which is used in histochemistry to detect amyloid, binds to a wide ar ⁇ ray of non-A ⁇ amyloids as well as to other protems with a high content of ⁇ -pleated sheet structures (W. Turnell, J.T. Finch, J. Mol . Biol . 227, 1205-1223 (1992) ) . Due to the extreme insolubility of amyloid, strong chaotropic agents or potent organic solvents are required for its dissolution (CL.
  • KLVFF an A ⁇ se ⁇ quence
  • the KLVFF peptide may serve as a model substance for the synthesis of non-peptide A ⁇ -ligands that interfere with the polymerization of A ⁇ molecules.
  • this region harbors at least one binding sequence required for the polymeri ⁇ zation of A ⁇ into amyloid fibrils. It was also demon- strated that short peptides incorporating A ⁇ -16-20 can function as ligands that bind to A ⁇ and inhibit the formation of amyloid fibrils. Since these peptide ligands are relatively small, they are amenable for identification of other organic molecules with simi- lar functional properties. Non-peptide homologues of KLVFF should be useful as pharmacological drugs for the treatment of Alzheimer's disease in the future.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compounds of formula (I) or (II), which are of interest especially for inhibition of polymerization of amyloid β peptide, as model substances for synthesis of amyloid β peptide-ligands, as tools for the identification of other organic compounds with similar functional properties and/or as ligands for detection of amyloid deposits using e.g. positron emission tomography (PET). Formula (II) is: R1 - A' - Y' - Leu - X' - Z' - B' - R2, in which X' means any group or amino acid imparting to the compound according to formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; Y' means any amino acid; Z' means any non-acidic amino acid; A' means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; B' means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; R1 is H or -CO-R3 bonded at the α-aminogroup of A'; R2 is H, -OR4 or NR5R6, all bonded to the α-carboxyl group of the α-carboxyterminal of B'; R3 and R4 are straight or branched carbon chain of 1-4 carbon atoms; R5 and R6 are independently H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH2)n-, where n is 4-5; and R1 and R2 together can form a hydrocarbon ring or heterocyclic ring; all α-amino acids being either D- or L-isomers.

Description

PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-p
Introduction The present invention relates to compounds, which are of special interest by their ability to bind to the KLVFF-sequence in the peptide amyloid β and to inhibit polymerization of the amyloid β peptide. The compounds according to the invention are e.g. useful as medicaments and as tools for identifi¬ cation of substances to be used m the treatment or prevention of amyloidosis.
Background of the invention Amyloidosis is a condition which is characterized by the deposition of amyloid in organs or tissues of the human or animal body, either as a primary disease of unknown cause or secondary to chronic disease, such as tuberculosis or osteomyeli- tis. In addition, it has also been found that the pre-eminent neuropathological feature of Alzheimer's disease (AD) , a chronic condition of brain atrophy, is the deposition of amyloid in the brain parenchyma and cerebrovasculature (D.J. Selkoe, Neuron 6, 487-498 (1991) ; D.J. Selkoe, Annu . Rev. Cel l Biol . 10, 373-403 (1994) ) .
The basic component of such amyloid is a peptide termed amyloid β, or Aβ (G.C. Glenner, CW. Wong, Bi ochem . Biophys . Res . Commun . 120, 885-890 (1984) ) . It is a 40 to 42 ammo acids long proteolytic frag¬ ment of the Alzheimer amyloid precursor protein (APP) , a protein expressed m most tissues (J. Kang, et al . , Na ture 325, 733-736 (1987)) . Genetic and neuropathological studies provide strong evidence for a central role of Aβ in the pathogenesis of AD, but the pathophysiological consequences of the amyloid deposition are still unclear. However, it has been suggested that Aβ polymers and amyloid are toxic to neurons, either directly or indirectly, and hence cause neurodegeneration (C. Behl, J. B. Davis, R.Lesley, D. Schubert, Cell 77, 817-827 (1994) ; D.T. Loo, et al . , ibid 90, 7951-7955 (1995) ) .
The amyloid associated with Alzheimer' s disease (AD) consists of thin fibrils of polymerized Aβ. A rational pharmacological approach for the prevention of amyloidogenesis would therefore be to use drugs that specifically interfere with Aβ-Aβ interaction and polymerization. Previous studies showed that Aβ polymerization m vi vo and m vi tro is a highly specific process, which probably involves an mtei- action between binding sequences in the Aβ peptide (J. Naslund, et a l . , Proc . Na tl . Aca d . Sci . USA 91, 8378-8382 (1994) ; J. Naslund, et al . , Biochem . Bio¬ phys . Res . Commun . 204, 780-787 (1994) ) .
Wood et al (S.J. Wood, R. Wetzel, J.D. Martin, M.R. Hurle, Biochemis try 34, 724-730 (1995) ) suggest that amino acid residues within or close to Aβ-16-20 are important for the adoption of the correct β-pleated sheet structure of Aβ and show that ammo acids 17-23 in the amyloid β peptide (Aβ) are essen- tial for fibril formation and probably make up the β-sheet core of the fibrils. In addition, Wood et al. have investigated the ability of their peptides to form amyloid fibrils in a solution containmg solely the mutated or the wild-type peptide. However, no method or principle which makes it possible to inhibit Aβ of wild type from forming amyloid fibrils is devised and no use of the peptides as medicaments is suggested.
WO 95/08999 relates to amelioration of amnesia in Alzheimer's disease caused by deposition of amy¬ loid β protein. Three peptides are disclosed, which overcome the amnestic effects of β-12-28, a peptide homologous to Aβ. In addition, WO 95/08999 describes the screening of several other peptides, which were neither significantly amnestic nor memory enhancing, of which one is KLVFF, SEQ. NO. 15 of the sequence listing therein.
In EP 0 584 452, novel amyloid precursor proteins and the sequences thereof are disclosed. Peptide sequences that comprise KLVFF are revealed. However, neither binding to amyloid β peptide nor any inhibition of the polymerization thereof is suggested.
Summary of the invention
Thus, the polymerization of the amyloid β pep- tide (Aβ) nto amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease.
In vi tro and m vivo studies of Aβ have shown that the Aβ molecules interact with a high degree of specificity during polymerization and fibril for- matron. It was assumed that ligands which bind to recognition sequences would be capable of inhibiting Aβ polymerization and possibly also dissolve pre¬ formed Aβ polymers m si tu . The strategy in finding such Aβ ligands was to identify critical binding re- gions m Aβ and, based on their sequences, develop a compound capable of blocking the Aβ-Aβ binding.
According to the invention, it was hypothesized that compounds capable of binding to regions in the Aβ-molecule critical for its polymerization might inhibit amyloid fibril formation, as described in more detail below.
According to the invention, it has now been found that the Lys-Leu-Val-Phe-Phe (KLVFF) sequence in Aβ is necessary for polymerization to occur. Pep- tides incorporating this sequence bind to Aβ and are capable of blocking the fibril formation of Aβ-1-40 and are therefore potentially useful as drugs. In addition, compounds have been found, which
1) are capable of binding to full-length Aβ,
2) are capable of blocking Aβ fibril formation and
3) do not form fibrils by themselves. In addition, it has also been found that alan e-substituted Aβ-1-28 (Ala at position 16,17,20), in contrast to wild-type Aβ-1-28, does not form fibrils.
Thus, it was concluded that the Lys-Leu-Val-Phe- Phe (16-20) motif serves as a structural basis for the development of peptide and non-peptide agents aimed at inhibiting amyloidogenesis m vi vo . This is a novel finding and the compounds are of utmost interest as being useful as drugs for Alzheimer' s disease.
Further, the findings according to the invention are even more surprising on the basis of what was concluded from WO 95/08999 mentioned above. In WO 95/08999, it was concluded that KLVFF is not a poten- tial candidate for the development of substances that can antagonize binding of Aβ and thus attenuate symp¬ toms and progression of AD. Even though the teaching of said WO publication indicates the opposite, according to the present invention, it has now been found that KLVFF on the contrary is most useful for the development of new compounds defmed by Formula (I) and (II) below.
Detailed description of the invention The present invention relates to compounds which are able to bind to the Lys-Leu-Val-Phe-Phe-sequence, or KLVTF-sequence, in the peptide amyloid β. More specifi¬ cally, the compounds according to the invention are defined by their formula (I) : Ri - A' - Y' - Leu - X' - Z' - B' - R2 (I) m which X' means any group or ammo acid imparting to the com¬ pound of formula (I) the ability to bind to the KLVFF- sequence m amyloid β peptide, or two ammo acids impart¬ ing the same ability, but with the proviso that one is not proline;
Y' means any amino acid;
Z' means any non-acidic ammo acid;
A' means a direct bond or an α-amino ac d bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group;
B' means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-termmal α-amino acid; Ri is H or -CO-Rj bonded at the α-amino group of A' ; R2 is H, -ORi or NR5R6, all bonded to the α-carboxyl group of the α-carboxytermmal of B' ;
R is a straight or branched carbon chain of 1-4 carbon atoms; R4 is a straight or branched carbon chain of 1-4 carbon atoms;
Rs and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH2)n-, where n is 4-5; Ri and Ri together can form a hydrocarbon ring or heterocyclic ring; and all the α-ammo acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe.
With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
With cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an ammo or a methoxy, ethoxy, propoxy or butoxy group. In a preferred embodiment of the present invention, the compound exhibits an ability to inhibit polymeriza¬ tion of amyloid β peptide.
In one embodiment of the invention, all the ammo acids of the compound are D-isomers.
In one embodiment of the invention, Y' is Lys, and in a particular embodiment of the mvention, Z' is Phe, resulting in a compound of the followmg formula: Ri-A' -NH-CHf- (CH?) 4-NH2]-CO-Leu-X' -NH-CH[-CH2-Ph]-CO-B' -R2 In an alternative embodiment of the invention,
Preferred are compounds, wherein X' is Val-Val.
In one embodiment of the present aspect of the invention, Ri is acetyl. In an alternative embodiment of the invention,
Ri is H. According to another embodiment, R? is H. Al¬ ternatively, Ri and R? are both H.
A second aspect of the present invention is the use of a compound of formula:
R, - A' Y' - Leu -X' - B' R? (ii:
m which
X' means any group or ammo acid imparting to the com- pound of formula (II) the ability to bind to the KLVFF- sequence in amyloid β peptide, or two ammo acids impart¬ ing the same ability, but with the proviso that one is not proline; Y' means any ammo acid; Z' means any non-acidic amino acid;
A' means a direct bond or an α-ammo acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; B' means a direct bond or an α-ammo acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-termmal α-amino acid; Rx is H or -CO-R3 bonded at the α-amino group of A' ; R? is H, -OR4 or NR5R6, all bonded to the α-carboxylgroup of the α-carboxytermmal of B' ;
R3 is a straight or branched carbon chain of 1-4 carbon atoms;
R,, is a straight or branched carbon chain of 1-4 carbon atoms;
R5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH2)n- where n is 4-5; Ri and R2 can together form a hydrocarbon ring or heterocyclic ring; and all the α-amino acids can be either D- or L-isomers; for inhibition of polymerization of amyloid β pep¬ tide, as a model substance for synthesis of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional properties or as ligand for detection of amyloid de¬ posits using e.g. positron emission tomography (PET) . With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
With cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms. Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.
In one embodiment of this second aspect of the mvention, a compound is used, wherein all the amino acids are D-isomers.
In a particular embodiment of this aspect of the invention, Y' is Lys. A particular embodiment is when Z' is Phe, resulting in a compound of the followmg formula:
Ri-A' -NH-CH[ (CH2) 4-NH2]-CO-Leu-X' -NH-CH[-CH?-Ph]-CO-B' R2. In an alternative embodiment, a compound is used, wherein Y' is Phe while Z' is any non-acidic ammo acid.
In a preferred embodiment of this aspect of the invention, a compound is used, wherem X' is Val-Val. In one embodiment of the use according to the invention, Ri is acetyl. Alternatively, Ri and/or R2 are H.
Yet another aspect of the present invention is a compound according to the mvention for use as a medicament .
Also claimed is the use of a compound, prefera¬ bly of the formula (I) or (II), which is able to bind to the KLVFF-sequence in amyloid β peptide and which has the ability to inhibit polymerization of amyloid β peptide, for the manufacture of a medicament for the treatment or prevention of amyloidosis, especially in the treatment or prevention of Alz¬ heimer s disease associated with amyloidosis, for the treatment or prevention of demens in patients with Down s syndrome, for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) or for the prevention of fibril forma¬ tion of human amyloid protem. Further, a last aspect of the present invention is a composition comprising a compound according to formula II and optionally a ligand capable of binding or interacting with the compound according to formula II and a carrier. Said composition can e.g. be adapted for injec¬ tion a liquid carrier or for oral administration in a tablet or capsule.
Carriers are known for persons skilled in the art . For clarification the followmg definitions are given: K is lysine (Lys) , L is leucine (Leu) , V is valine (Val) , F is phenylalanine (Phe) , A is alanine (Ala) and E is glutamic acid (Glu) .
As used herein, "any group giving the compound ac- cording to formula (I) the ability to bind to the KLVFF-sequence in the amyloid β peptide" means that this group gives the compound a structure, which can fulfil the requirements given in claim 1.
The hydrocarbon ring or heterocyclic ring has preferably 4-6 atoms, preferably C, N and S.
Description of the figures
Fig. 1 A and B. Aβ-amyloid polymerization.
Fig. 2A. Ten-mers corresponding to consecutive sequences of Aβ-1-40. Radioactivity bound to the filter was detected by autoradiography and quantified by densitometry.
Fig. 2B. EVHHQKLVFF and N and C-terminal trun¬ cated fragments were synthesized and analyzed for affinity to 125I-labelled Aβ-1-40.
Fig. 2C. Each ammo acid residue in KLVFF was systematically replaced with Ala and analyzed for affinity to 125I-labelled Aβ-1-40.
Fig 2D. Ξensorgram from surface plasmon reso- nance spectroscopy (BIAcore 2000) .
Fig. 3 A and B. Content of non-aggregated peptide in the supernatants from incubations of wild- type and Ala-substituted Aβ-1-28 as analyzed by HPLC.
EXPERIMENTAL Example 1 a) Ten-mers corresponding to consecutive sequences of Aβ-1-40 were synthesized on a filter matrix using the SPOT-technique (the peptides were synthesized essen- tially as described by Frank [R. Frank, Tetrahedron 42, 9217-9232 (1992) ] . Briefly, a spacer correspond¬ ing to 2 molecules of β-alanine was coupled to cellu- lose membranes (Whatman IChr) . The peptides were syn¬ thesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated ammo acids (AMS Biotechnology) dissolved m N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.) . We synthesized the thirty-one possible 10-mers of the Aβ-1-40. Peptide no. 1 corresponds to ammo acids 1-10, peptide no. 2 to ammo acids 2-11 etc. The filter-bound peptides were incubated with radioactive Aβ-1-40. Followmg washing of the filter in high-salt buffer, bound radioactivity was esti¬ mated by autoradiography and densitometry. Followmg blocking with 0.05° Tween-20 in Tπs-buffered saline (TBS), the filter was incubated in the presence of 20 μM 125I-labelled Aβ-1-40 at 20°C for 12 h TBS, pH 7.3, supplemented with 1% bovine serum albumin. The filter was then washed repeatedly the same buffer contammg 0.5 M NaCl and dried. Radioactivity bound to the filter was visualized by autoradiography and quantitated using a densitometer. b) Peptide no. 11 (EVHHQKLVFF) and indicated N- and C-termmal truncated fragments were synthesized using the same technique as described above and analyzed for affinity to 125I-labelled Aβ-1-40. c) Sensorgram from BIAcore 2000. Aβ-1-40, at three different concentrations in running buffer, pH 7.4. Aβ-1-40 was injected durmg 10 minutes over a sensor- chip derivatized with the peptide KLVFF-βA-βA-C. d) Each ammo acid residue KLVFF was systemati- cally replaced with A and analyzed for affinity to l Y-labelled Aβ-1-40. Non-specific interactions have been compensated for by subtracting the signal from a surface derivatized with C alone.
Results a) The measured binding should be interpreted as semiquantative, since the coupling efficiency and therefore the amount of peptide per spot may vary. A region located in the central part of Aβ (Aβ-9-18 to Aβ-13-22) displayed prominent binding of radioactive Aβ-1-40. Another binding region was the hydrophobic C-termmus of the molecule (D. Burdick, et al , J.
B ol . Chem . 267, 546-554 (1992) ) but binding here was considerably weaker (Fig 2A) . b) Being located the centre of the binding region, peptide no. 11 (corresponding to Aβ-11 - 20) was selected for further studies. This peptide, as well as N- and C-termmal fragments thereof, were synthe¬ sized using the same tech ique as described previ¬ ously. The shortest peptide still displaying high Aβ binding capacity had the sequence KLVFF, correspond- mg to ammo acids 16-20 of Aβ (Fig. 2B) . By system¬ atically substituting the ammo acid residues in the KLVFF sequence with alanine, we found that the first, second and fifth residues (i.e. KLXXT) were critical for binding (Fig. 2C) . c) The interaction between soluble Aβ-1-40 and immo¬ bilized KLVFF was monitored in real-time (Fig. 2D) using surface plasmon resonance spectroscopy (BIAcore, Pharmacia) (BIAcore 2000 (Pharmacia Biosen¬ sor AB, Sweden) was used for real-time studies based on surface plasmon resonance spectroscopy. The pep¬ tide was immobilized using thiol coupling. The run¬ ning buffer consisted of 10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA and 0.05% surfactant P20 as described. [U. Jansson, M. Malmqvist, Adv. Bi osens . 2, 291-336 (1992)]) . The binding was not saturable, indicating that Aβ-1-40 bound to immobilized KLVFF could inter¬ act with other Aβ-1-40 molecules m a polymerization reaction. d) AA served as linker between the active peptide and the chip (upper trace) and cysteine alone , indi¬ cating non-specific binding, (C) as control (lower trace) . Arrows indicate start and stop of injection (Fig. 2D) .
Example 2 To investigate if the KLXXF motif was required for Aβ polymerization, we synthesized Aβ-1-28, a well-studied Aβ fragment that readily forms amyloid fibrils (D.A. Kirschner, et a l . , Proc . Na tl . Acad . Sci . USA 84, 6953-6957 (1987); CJ. Barrow, M.G. Zagorski, Science 253, 179-82 (1991); C. Nordstedt, et a l . , J. Biol . Chem . 269, 30773-30776 (1994)) and mutated Aβ-1-28 where the KLVFF sequence was substi¬ tuted with AAVFA (Aβ-1-28AAVFA) .
Aβ-1-28 (Fig. 3 A) and Aβ-1-28AAVFA (Fig. 3 B) were incubated at 200 μM in TBS for 24 h at 37°C in a shaking water bath. After incubation, the tubes were centrifuged at 20,000g for 20 mm and the content of non-aggregated peptide in the supernatants (Fig. 3 A, B) was analyzed using an established C4 RPLC system (12) whereas the aggregated peptides in the pellets were analyzed by electron microscopy after adsorp¬ tion to formvar-coated grids and negative staining with 2°o uranyl acetate in water.
Results
Followmg incubation at a concentration of 200 μM for 24 h at 37°C, Aβ -1-28 aggregated (Fig. 3A) and formed large fibril bundles, whereas Aβ-1-28AAVFA almost completely failed to aggregate (Fiq. 3B) and only formed a few dispersed fibrils.
Example 3
Aβ-1-40 was incubated at 100 μM m TBS for 48 h at 37CC in a shaking water bath, either alone or together with 100 μM AcKLVFFWH2- The polymerized material was ad¬ sorbed to formvar-coated grids and negatively stained with 2° uranyl acetate in water. Results
Incubation of synthetic Aβ-1-40 at 100 μM for 48 h at 37°C m a physiological buffer led to polymeri- zation and formation of amyloid fibrils arranged m parallel densely packed bundles, as previously shown (C Nordstedt, et al . , J. Biol . Chem . 269, 30773-30776 (1994) ) . When Aβ-1-40 was comcubated with ΛcQKLVFFITO2 at equimolar concentrations, this type of fibrils did not form. Instead, only a few occasional fibrils embedded in a diffuse background of small rod-like aggregates, similar to those formed by ΛcQKLVFFNH? itself, could be detected.
Example 4
The peptides were synthesized essentially as described by Frank (Frank R, 1992, Tetrahedron 42:9217-9232) . Briefly, a spacer corresponding to 2 molecules of β-alanme was coupled to cellulose me - branes (Whatman XX) . The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated ammo acids (AMS biotech¬ nology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.
Results
The KLXXF motif in the Aβ molecule is not only critical for polymerization and fibril formation. Durmg non-amyloidogenic processing of APP, the mole- cule is cleaved between ammo acid residues Y^ ancι L17 (F.S. Esch, et a l . , Science 248, 1122-1124 (1990)), leading to the formation of a fragment of Aβ termed p3 and corresponding to Aβ-17-40 or Aβ-17-42 (C Haass, A.Y. Hung, M.G. Schlossmacher, D.B. Teplow, D. J. Selkoe, J. Biol . Chem . 268, 3021-3024 (1993)) . Through this metabolic pathway the present binding sequence is disrupted. This may explain why p3 is not capable of forming amyloid m vi tro or in vi vo (J. Naslund, et al . , Proc . Na tl . Acad . Sci . USA 91, 8378-8382 (1994) ; J. Naslund, et al . , Bi ochem . Bi ophys . Res . Commun . 204, 780-787 (1994) ) . The KLXXF motif is highly sequence specific. The most apparent example of this is the findmg that substi¬ tution of a single amino acid leads to virtually complete loss of Aβ binding capacity.
Example 5
In an additional series of experiments, it was demonstrated that KLVFF binds stereo specifically to the homologous sequence in Aβ (i.e. Aβ-16-20) . By screening combinatorial pentapeptide libraries exclusively composed of D-amino acids (lowercase) with labelled KLVFF, several ligands with a motif containing phenylalanine (f) the second and leucine (1) in the third position were identi¬ fied (e.g. Iflrr) . By using a short peptide in the screen¬ ing, known to bind to a region in Aβ critical for its polymerization (i.e. KLVFF), the risk of identifying
D-pentapeptides that interact with nonrelevant regions in Aβ (N- or C-terminal to Aβ-16-20) was eliminated. Like KLVFF, the D-amino acid ligands were found not only to bind to Aβ but also to inhibit amyloid fibril formation. Since peptides built up of D-amino acids are resistant to proteolytic degradation, these ligands may be beneficial for inhibition of amyloidogenesis in vivo. The results further indicate that KLVFF will be useful in the identi¬ fication of small organic molecules (e.g. by screening of substance libraries) with the ability to bind to Aβ in this relevant region and inhibit amyloid fibril formation (candidate drugs for the treatment of Alzheimer disease and other related amyloidoses) . Discussion and conclusion
Previous studies of putative inhibitors of amy¬ loid fibril formation showed that cyclodextrins (P.Camilleπ, N.J. Haskmd, D.R. Howlett, FEBS Let t . 341, 256-258 (1994)) and Congo red (A. Lorenzo, B. Yankner, Proc. Na tl . Acad. Sci . USA 91, 12243-12247 (1994) ) may have such properties. The usefulness of these molecules as lead or model substances in devel¬ opment of anti-Alzheimer amyloid drugs is, however, compromised by their relative lack of specificity. Cyclodextrins have primarily been used to increase the solubility of a wide range of lipophilic drugs and it is unlikely that they would display any speci¬ ficity for Aβ m vi vo . Congo red, which is used in histochemistry to detect amyloid, binds to a wide ar¬ ray of non-Aβ amyloids as well as to other protems with a high content of β-pleated sheet structures (W. Turnell, J.T. Finch, J. Mol . Biol . 227, 1205-1223 (1992) ) . Due to the extreme insolubility of amyloid, strong chaotropic agents or potent organic solvents are required for its dissolution (CL. Masters, et ai., Proc . Na t l . Aca d . Sci . USA 82, 4245-4249 (1985) ), the concept of dissolving amyloid deposits m si t u under physiological conditions may seem futile. However, the bulk of the individual mole¬ cules m amyloid are probably not joined by covalent bonds and the deposition of Aβ mto amyloid is, at least at some stages, a dynamic and reversible proc- ess (J.E. Maggio, et a l . , ibid. , 89, 5462-5466
(1992) ) . Hence, a molecule capable of binding to a site in the Aβ molecule that is critical for fibril formation with an affinity higher than native Aβ should have reasonable chances to inhibit amyloid growth and maybe also specifically dissolve amyloid fibrils . In conclusion, we have identified an Aβ se¬ quence, KLVFF, which Is required for amyloid fibril formation. The KLVFF peptide may serve as a model substance for the synthesis of non-peptide Aβ-ligands that interfere with the polymerization of Aβ molecules.
Previous studies suggested that amino acid resi¬ dues within or close to Aβ-16-20 are important for the adoption of the correct β-pleated sheet structure of Aβ (18) and the proteolytic processing of its precursor (14 ) .
We have now shown that this region harbors at least one binding sequence required for the polymeri¬ zation of Aβ into amyloid fibrils. It was also demon- strated that short peptides incorporating Aβ-16-20 can function as ligands that bind to Aβ and inhibit the formation of amyloid fibrils. Since these peptide ligands are relatively small, they are amenable for identification of other organic molecules with simi- lar functional properties. Non-peptide homologues of KLVFF should be useful as pharmacological drugs for the treatment of Alzheimer's disease in the future.

Claims

CLAIMS 1. A compound havmg the formula
Ri - A' - Y' - Leu -X' - Z' - B' - R? (I)
in which
X' means any group or am o acid imparting to the com¬ pound of formula (I) the ability to bind to the KLVFF- sequence in amyloid β peptide, or two ammo acids lmpart- mg the same ability, but with the proviso that one is not proline;
Y' means any am o acid; Z' means any non-acidic amino acid; A' means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group;
B' means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-termmal α-ammo acid;
Ri is H or -CO-R^ bonded at the α-amino group of A' ;
R2 is H, -OR4 or NR5R6, all bound to the α-carboxyl group of the α-carboxytermmal of B' ;
R3 is a straight or branched carbon chain of 1-4 carbon atoms;
R4 is a straight or branched carbon chain of 1-4 carbon atoms;
R5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH2)n- , where n is 4- 5;
Ri and R> together can form a hydrocarbon ring or hetero¬ cyclic ring; and all the α-ammo acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe. 2. A compound according to claim 1, which exhibits an ability to inhibit polymerization of amyloid β pep¬ tide. 3. A compound according to any one of claims 1-2, wherem all the ammo acids are D-isomers. . A compound according to any one of the preceding claims, wherem Y' is Lys. 5. A compound according to claim 4, wherem Y' is
Figure imgf000020_0001
6. A compound accordmg to any one of claims 1-3, wherem Y' is Phe.
7. A compound according to any one of the pre- ceedmg claims, wherem X' is Val-Val.
8. A compound according to any one of the pre¬ ceding claims, wherem Ri is acetyl.
9. A compound accordmg to any one of claims 1- 8, wherein Ri is H and/or R2 is H. 10. Use of a compound of formula
Ri - A' - Y' - Leu -X' - Z' - B' - R2 (II)
in which X' means any group or ammo acid imparting to the com¬ pound of formula (II) the ability to bind to the KLVFF- sequence in the amyloid β peptide, or two ammo acids im¬ parting the same ability, but with the proviso that one is not proline; Y' means any ammo acid;
Z' means any non-acidic ammo acid;
A' means a direct bond or an α-ammo acid bonded at the carboxyl terminal of the α-carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group;
B' means a direct bond or an α-ammo acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-termmal α-amino acid; Ri is H or -CO-R^ bonded at the α-ammo group of A' ; R^ is H, -OR4 or NR5R6 all bound to the α-carboxyl group of the α-carboxytermmal of B' ; R, is a straight or branched carbon chain of 1-4 carbon atoms;
R^ is a straight or branched carbon chain of 1-4 carbon atoms; R and Rb independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH2)n-, where n is 4-5; Ri and R^ together can form a hydrocarbon ring or hetero¬ cyclic ring; all the α-ammo acids can be either D- or L-isomers; for inhibition of polymerization of amyloid β pep¬ tide, as model substance for synthesis of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional properties or as a ligand in PET (positron emission tomography) .
11. Use according to claim 10, wherem all the ammo acids of the compound are D-isomers.
12. Use according to any one of claims 10-11, wherem Y' is Lys.
13. Use according to claim 12, wherem Y' is Lys and Z' is Phe.
14. Use accordmg to any one of claims 10-11, wherem Y' is Phe. 15. Use according to any one of claims 10-14, wherem X' is Val-Val.
16. Use according to any one of claims 10-15, wherem Rx is acetyl.
17. Use according to any one of claims 10-15, wherem Ri is II and/or R2 is H.
18. A compound according to any one of claims 1- 9 for use as a medicament.
19. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the treatment or prevention of amyloidosis.
20. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the treatment or prevention of Alzheimer disease as¬ sociated with amyloidosis.
21. Use of a compound accordmg to any one of claims 1-9 for the manufacture of a medicament for the treatment or prevention of demens in patients with Down s syndrome.
22. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) .
23. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the prevention of fibril formation of human amyloid protein. 24. A composition comprising a compound accord¬ mg to any one of claims 1-9 and optionally a ligand capable of binding or interacting with the compound according to formula 1 and a carrier.
25. A composition according to claim 24, which is adapted for injection or oral administration.
PCT/SE1996/001621 1995-12-12 1996-12-09 PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) WO1997021728A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP96940740A EP0866805A1 (en) 1995-12-12 1996-12-09 PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
AU10728/97A AU1072897A (en) 1995-12-12 1996-12-09 Peptide binding the klvff-sequence of amyloid beta
US09/095,106 US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β
US09/850,061 US20020094957A1 (en) 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta
US10/721,774 US7288523B2 (en) 1995-12-12 2003-11-26 Peptide binding the KLVFF-sequence of amyloid-β

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9504467A SE9504467D0 (en) 1995-12-12 1995-12-12 Peptide
SE9504467-3 1995-12-12
US938695P 1995-12-29 1995-12-29
US60/009,386 1995-12-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09095106 A-371-Of-International 1996-12-09
US09/095,106 Continuation US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β
US09/850,061 Division US20020094957A1 (en) 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta

Publications (1)

Publication Number Publication Date
WO1997021728A1 true WO1997021728A1 (en) 1997-06-19

Family

ID=26662451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1996/001621 WO1997021728A1 (en) 1995-12-12 1996-12-09 PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)

Country Status (4)

Country Link
US (3) US6331440B1 (en)
EP (1) EP0866805A1 (en)
AU (1) AU1072897A (en)
WO (1) WO1997021728A1 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
EP0915088A1 (en) * 1997-10-31 1999-05-12 F. Hoffmann-La Roche Ag D-Proline derivatives
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO2000052048A1 (en) * 1999-03-04 2000-09-08 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO2001066576A1 (en) * 2000-03-07 2001-09-13 Biowindow Gene Development Inc. Shanghai A novel polypeptide-homo amyloid 11 and polynucleotide encoding said polypeptide
WO2002057796A2 (en) * 2001-01-18 2002-07-25 Shell John W Compounds for treating pathologies associated with molecular crystallization
DE10230141A1 (en) * 2002-07-04 2004-02-05 Labor Diagnostik Gmbh Leipzig Process for the enrichment and detection of modified prion proteins (PrPSc)
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2006095041A1 (en) * 2005-03-09 2006-09-14 Consejo Superior De Investigaciones Científicas Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
US7288523B2 (en) 1995-12-12 2007-10-30 Neurochem (International) Limited Peptide binding the KLVFF-sequence of amyloid-β
EP1870419A2 (en) * 1999-03-04 2007-12-26 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
EP1951750A2 (en) * 2005-11-10 2008-08-06 Roskamp Research LLC Modulation of angiogenesis by a-beta peptide fragments
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7977316B2 (en) 1999-06-01 2011-07-12 Elan Pharmaceuticals, Inc. Prevention and treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2014103481A1 (en) * 2012-12-27 2014-07-03 独立行政法人科学技術振興機構 Cyclic peptide and pharmaceutical product containing same
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20070021929A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
WO2002044730A1 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20070020662A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US6977723B2 (en) * 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6875744B2 (en) * 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
EP1379265A4 (en) * 2001-03-28 2005-09-14 Helix Biomedix Inc Short bioactive peptides and methods for their use
US20050209157A1 (en) * 2001-03-28 2005-09-22 Owen Donald R Short bioactive peptides and methods for their use
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
WO2004024090A2 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004100998A2 (en) 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20060069010A1 (en) * 2003-10-17 2006-03-30 Senicure Llc Detoxification depot for Alzheimer's disease
PL1853620T3 (en) * 2005-02-09 2012-07-31 Helix Biomedix Inc Antimicrobial hexapeptides
US20100130416A1 (en) * 2005-11-10 2010-05-27 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR20180088828A (en) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 N-terminal epitopes in amyloid beta and morphologically-selective antibodies thereto
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20210140980A1 (en) * 2018-01-04 2021-05-13 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
CN110780076B (en) * 2019-10-24 2023-02-17 南开大学 Preparation method and application of sensitive beta-amyloid protein nano fluorescent probe

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584452A1 (en) * 1992-05-01 1994-03-02 American Cyanamid Company Novel amyloid precursor proteins and methods of using same
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1995008999A1 (en) * 1993-09-29 1995-04-06 City Of Hope AMELIORATION OF AMNESIA IN ALZHEIMER'S DISEASE CAUSED BY DEPOSITION OF AMYLOID β PROTEIN
WO1996034887A2 (en) * 1995-05-05 1996-11-07 Imperial College Of Science, Technology & Medicine Antisense peptides

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116768A (en) 1975-04-29 1978-09-26 (Zaidanhojin) Sagami Chemical Research Center Process for producing a peptide
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5002872A (en) 1989-05-10 1991-03-26 W. R. Grace & Co.-Conn. Enzyme mediated coupling reactions
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
AU667578B2 (en) 1992-08-27 1996-03-28 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
WO1995005393A2 (en) 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
DK96493D0 (en) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
JPH10500686A (en) 1994-05-20 1998-01-20 ノババックス インコーポレイテッド Antibacterial oil-in-water emulsion
JP3659261B2 (en) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト Targeted heterojunction of a recombinant protein to a multifunctional complex
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ES2175083T3 (en) 1995-03-14 2002-11-16 Praecis Pharm Inc AMULOID AGGREGATION MODULATORS.
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH11508126A (en) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー Multimeric protein
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0866805A1 (en) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
EP0883686A1 (en) 1996-02-26 1998-12-16 Morphosys Gesellschaft für Proteinoptimierung mbH Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
DE69733655T2 (en) 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDE AGGREGATION REGULATING PEPTIDES WITH D-AMINO ACIDS
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
FR2761058B1 (en) * 1997-03-19 1999-05-21 Goemar Lab Sa COMPOSITION AND METHOD FOR STIMULATING THE GERMINATION OF POLLEN GRAINS
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
ES2253839T3 (en) 1997-12-03 2006-06-01 Neuralab, Ltd. SUPPRESSION OF CHANGES RELATED TO AMILOID BETA IN THE DISEASE OF ALZHEIMER.
NO314086B1 (en) 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
PT1078005E (en) 1998-05-21 2010-08-30 Univ Tennessee Res Foundation Methods for amyloid removal using anti-amyloid antibodies
JP2002526419A (en) 1998-10-05 2002-08-20 ファーメクサ エイ／エス Novel methods for therapeutic vaccination
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
CA2361124A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
PT1161449E (en) 1999-03-04 2007-10-12 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising d-amino acids
EP1173480B1 (en) 1999-05-05 2008-01-16 Neurochem (International) Limited Stereoselective antifibrillogenic peptides
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US20070135337A2 (en) 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1251837A2 (en) 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584452A1 (en) * 1992-05-01 1994-03-02 American Cyanamid Company Novel amyloid precursor proteins and methods of using same
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1995008999A1 (en) * 1993-09-29 1995-04-06 City Of Hope AMELIORATION OF AMNESIA IN ALZHEIMER'S DISEASE CAUSED BY DEPOSITION OF AMYLOID β PROTEIN
WO1996034887A2 (en) * 1995-05-05 1996-11-07 Imperial College Of Science, Technology & Medicine Antisense peptides

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462171B1 (en) 1995-06-07 2002-10-08 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US7175828B2 (en) 1995-10-27 2007-02-13 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6689752B2 (en) 1995-10-27 2004-02-10 Praecis Pharmaceuticals, Incorporated Modulators of β-amyloid peptide aggregation comprising D-amino acids
US7288523B2 (en) 1995-12-12 2007-10-30 Neurochem (International) Limited Peptide binding the KLVFF-sequence of amyloid-β
EP1586584A1 (en) * 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6512001B1 (en) 1997-10-31 2003-01-28 Hoffmann-La Roche Inc. D-proline derivatives
US6262089B1 (en) 1997-10-31 2001-07-17 Hoffman-La Roche Inc. D-proline derivatives
EP0915088A1 (en) * 1997-10-31 1999-05-12 F. Hoffmann-La Roche Ag D-Proline derivatives
US6740760B2 (en) 1997-10-31 2004-05-25 Hoffmann-La Roche Inc. D-proline derivatives
US6103910A (en) * 1997-10-31 2000-08-15 Hoffmann-La Roche Inc. D-proline derivatives
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787138B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787140B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6818218B2 (en) 1997-12-02 2004-11-16 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787144B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787139B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787143B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7803774B2 (en) 1999-03-04 2010-09-28 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation
AU781292B2 (en) * 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1870419A3 (en) * 1999-03-04 2008-01-02 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
WO2000052048A1 (en) * 1999-03-04 2000-09-08 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
US6610658B1 (en) 1999-03-04 2003-08-26 Praecis Pharmaceuticals Inc. Modulators of μ-amyloid peptide aggregation
EP1870419A2 (en) * 1999-03-04 2007-12-26 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
WO2000068263A3 (en) * 1999-05-05 2001-05-03 Neurochem Inc Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US8124081B2 (en) 1999-06-01 2012-02-28 Crimagua Limited Prevention and treatment of amyloidogenic diseases
US7977316B2 (en) 1999-06-01 2011-07-12 Elan Pharmaceuticals, Inc. Prevention and treatment of amyloidogenic diseases
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
US7125838B1 (en) 1999-07-28 2006-10-24 Senexis Limited Peptides containing N-substituted L-amino acids for preventing β-strand association
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
WO2001066576A1 (en) * 2000-03-07 2001-09-13 Biowindow Gene Development Inc. Shanghai A novel polypeptide-homo amyloid 11 and polynucleotide encoding said polypeptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002057796A2 (en) * 2001-01-18 2002-07-25 Shell John W Compounds for treating pathologies associated with molecular crystallization
WO2002057796A3 (en) * 2001-01-18 2003-03-27 John W Shell Compounds for treating pathologies associated with molecular crystallization
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
DE10230141A1 (en) * 2002-07-04 2004-02-05 Labor Diagnostik Gmbh Leipzig Process for the enrichment and detection of modified prion proteins (PrPSc)
DE10230141B4 (en) * 2002-07-04 2004-07-15 Priontype Gmbh Method and kit for the enrichment and detection of modified prion proteins (PrPSc)
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US7932048B2 (en) 2005-03-09 2011-04-26 Consejo Superior De Investigaciones Cientificas Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
ES2259270A1 (en) * 2005-03-09 2006-09-16 Consejo Superior De Investigaciones Cientificas Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
WO2006095041A1 (en) * 2005-03-09 2006-09-14 Consejo Superior De Investigaciones Científicas Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
EP1951750A2 (en) * 2005-11-10 2008-08-06 Roskamp Research LLC Modulation of angiogenesis by a-beta peptide fragments
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments
EP1951750A4 (en) * 2005-11-10 2009-12-09 Roskamp Res Llc Modulation of angiogenesis by a-beta peptide fragments
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9585956B2 (en) 2007-06-12 2017-03-07 Ac Immune S.A. Polynucleotides encoding anti-amyloid beta monoclonal antibodies
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
JP2014141445A (en) * 2012-12-27 2014-08-07 Japan Science & Technology Agency Cyclic peptide and pharmaceutical product containing the same
WO2014103481A1 (en) * 2012-12-27 2014-07-03 独立行政法人科学技術振興機構 Cyclic peptide and pharmaceutical product containing same
US9745349B2 (en) 2012-12-27 2017-08-29 Japan Science And Technology Agency Cyclic peptide and pharmaceutical product containing same

Also Published As

Publication number Publication date
US20040157781A1 (en) 2004-08-12
US6331440B1 (en) 2001-12-18
EP0866805A1 (en) 1998-09-30
US20020094957A1 (en) 2002-07-18
US7288523B2 (en) 2007-10-30
AU1072897A (en) 1997-07-03

Similar Documents

Publication Publication Date Title
EP0866805A1 (en) PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
EP0843516B1 (en) Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5721106A (en) In Vitro method for screening β-amyloid deposition
Sadowski et al. A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice
JP5137400B2 (en) Peptides for diagnosing and treating amyloid-related diseases, antibodies thereto, and methods of use thereof
EP0787146B1 (en) Compounds and methods for inhibiting beta-protein filament formation and neurotoxicity
CA2697361C (en) Alpha-synuclein binding diagnostic agent
JP2003530554A (en) Prion binding peptide ligands and methods of using the same
CA2262453A1 (en) Modulators of .beta.-amyloid peptide aggregation comprising d-amino acids
RU2260599C2 (en) MODULATING AGENT FOR AGGREGATION OF β-AMYLOID FOR AGGREGATION INHIBITION OF NATURAL β-AMYLOID OR FOR TREATMENT OF SUBJECT WITH DISORDER ASSOCIATED WITH β-AMYLOIDOSIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR DETECTION OF NATURAL β-AMYLOID PEPTIDE IN BIOLOGICAL SAMPLE
Liu et al. Study on the efficiency and interaction mechanism of a decapeptide inhibitor of β-amyloid aggregation
JP4454230B2 (en) β-secretase substrate and use thereof
JP2006506942A (en) Peptides for diagnosing and treating amyloid-related diseases, antibodies thereto, and methods of use thereof
Lívia Aggregation Studies, Design and Synthesis of Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease
Vyas Stabilization of secondary structure of synthetic Alzheimer beta-amyloid protein analogs in the presence of aluminum (III) ions
Weinreb Mechanistic studies of beta protein and NAC amyloid formation in Alzheimer's disease and biochemical probes of NACP function
Come Models for protein assembly in the prion diseases
Jarrett Amyloid fibril formation in Alzheimer's disease
Zhang Synthesis and application of beta amyloid congeners to study the mechanism of amyloid formation in Alzheimer's disease
Jost Synthesis and biological investigation of ß-amyloid peptides
Blandl Structure-function relationships of the NMDA receptor antagonist peptides conantokin-G and conantokin-R
WO2009100893A1 (en) Neuroprotective peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996940740

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97521984

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996940740

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642